Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Basal rate Stories

2014-01-29 12:27:15

LAUSANNE, Switzerland, January 29, 2014 /PRNewswire/ -- Click here for Picture 1 [http://www.debiotech.com/news/images/nw181_1.png ] The JewelPUMP2, which will be unveiled for the first time at the ATTD 2014 congress on February 5th in Vienna, is a new product dedicated to the Diabetes Type 2 market, based on Debiotech's innovative JewelPUMP platform. The JewelPUMP2 has been entirely re-designed to address the very specific market of Type 2 patients, requiring an...

2013-06-04 12:27:44

--- Valeritas Expanding V-Go US Commercial Operations --- BRIDGEWATER, N.J., June 4, 2013 /PRNewswire/ -- Valeritas, makers of the V-Go(® )insulin delivery device, today announced that they have closed a structured debt financing with Capital Royalty L.P. which provides Valeritas with up to $100 million to further support the commercialization of the V-Go. "We are pleased to have Capital Royalty as a financial partner," said Kristine Peterson, Valeritas Chief Executive Officer....

2013-05-22 12:30:04

-- Studies Presented at ISPOR Meeting Underscore Potential Cost Savings for Improved Diabetes Control -- NEW ORLEANS, May 22, 2013 /PRNewswire/ -- Hemoglobin A1C levels increased over a four-year period for commercially-insured patients with Type 2 diabetes, while modest improvements in A1C control has been shown to improve health outcomes and can lead to substantial healthcare cost savings, according to two studies presented at the International Society for Pharmacoeconomics and...

2013-05-02 16:28:17

--- Data Presented at the American Association of Clinical Endocrinologists 22nd Annual Scientific and Clinical Congress --- BRIDGEWATER, N.J., May 2, 2013 /PRNewswire/ -- Valeritas, makers of the V-Go(® )insulin delivery device, announced new interim analysis from an observational study today that suggest patients with Type 2 diabetes who switched to the V-Go insulin delivery device from their previous baseline treatment experienced potentially significant improved glycemic...

2012-11-12 08:25:01

BRIDGEWATER, N.J., Nov. 12, 2012 /PRNewswire/ -- Valeritas announced today the results from a recent retrospective analysis that looked at data relating to the clinical experience and feedback of patients with Type 2 diabetes who used the V-Go(TM), a wearable device for the delivery of insulin. The retrospective analysis of self-reported data from V-Go patients has been published in the current issue of Endocrine Practice, a peer-reviewed journal of the American College of Endocrinology and...

2012-07-18 10:26:45

INDIANAPOLIS, July 18, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Accu-Chek Combo system for insulin pump therapy. The Accu-Chek Combo system seamlessly combines a blood glucose meter with an insulin pump, which are able to exchange data in both directions via Bluetooth wireless technology. The meter not only enables the user to quickly test blood glucose levels: It allows for...

2012-05-22 02:27:05

WESTPORT, Conn., May 22, 2012 /PRNewswire/ -- Valeritas, the maker of V-Go(TM) Disposable Insulin Delivery Device, a new, simple disposable device for the delivery of insulin designed especially for adults with type 2 diabetes, has selected dLife to support its state-of-the-art patient engagement program. dLife, the number-one resource and community network for people living with diabetes, and Valeritas have co-developed V-Go Life, a comprehensive diabetes lifestyle management and support...

2011-09-12 06:30:00

BRIDGEWATER, N.J., Sept. 12, 2011 /PRNewswire/ -- Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it has completed a significant Series C round of financing of $150 million. This financing will support the commercialization of the V-Go(TM) Disposable Insulin Delivery Device, which provides basal-bolus insulin therapy for adult patients with diabetes who require insulin. Welsh, Carson,...

2011-07-25 06:30:00

BRIDGEWATER, N.J., July 25, 2011 /PRNewswire/ -- Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it received CE Mark approval for its V-Go(TM) Disposable Insulin Delivery Device as well as ISO 13485: 2003 Quality Management System Certification. The V-Go is designed to provide simple basal-bolus therapy for adults who require insulin therapy. "These are important corporate milestones for...

2011-03-01 06:30:00

BRIDGEWATER, N.J., March 1, 2011 /PRNewswire/ -- Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that the U.S. Food and Drug Administration has cleared the company's V-Go Disposable Insulin Delivery Device for use with Novo Nordisk's NovoLog® for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients...